PharmaLytica 2021 Hyderabad review.

abc

abc

Gujarat govt in talks with Bharat Biotech to ramp up production of Covaxin: DBT

The production capacity of Covaxin is expected to reach more than 10 crore doses per month by September

15th May, 2021 Mumbai

To ramp up production of Covaxin, the Gujarat government, along with Hester Biosciences and OmniBRx, has firmed up its discussions with Bharat Biotech to produce 20 million doses per month, the Department of Biotechnology (DBT) said on Saturday.

This is in addition to ramping up production capacity by roping in three public sector companies -- Haffkine Biopharmaceutical Corporation Ltd, Mumbai, a PSU under the Maharashtra government, Indian Immunologicals Limited (IIL), Hyderabad, a facility under National Dairy and Bharat Immunologicals and Biologicals Limited (BIBCOL), Bulandshahr, a PSU under the DBT.

The DBT had announced the plan last month to ramp up the production capacity.

Further, Gujarat Biotechnology Research Centre, Department of Science and Technology Govt of Gujarat along with Hester Biosciences and OmniBRx has also firmed up its discussions with Bharat Biotech to scale up the COVAXIN technology and to produce minimum 20 million doses per month. Technology transfer agreements have been finalised with all manufacturers, the DBT added.

Under Mission COVID Surkasha, financial support is being provided as grant from the Centre to the tune of approximately Rs 65 crore to Bharat Biotech's new Bangalore facility which is being repurposed to increase the capacity of vaccine.

The production capacity of Covaxin is expected to reach more than 10 crore doses per month by September, the DBT said.

abc

abc

×

This Website Uses Cookies for Google Analytics, to improve your experience and to show you personalized advertising. By using this website you agree to our COOKIES AND PRIVACY POLICY...Learn More